DAFTAR PUSTAKA
1. Barhnhill RL, Croeson AN, Magro CM, Piepkorn MW. Dermatopathology. 3th ed. New York:McGraw-Hill Medical; 2010: 578-590. [cited on 2013 Aug 01] 2. Gawkrodger DJ. Dermatology: An Illustrated Colour Text. 3th ed. London:
Churchill Livingstone; 2002: 2,3,96,97. [cited on 2013 Aug 01]
3. Tuzun Y, Kutlubay Z, Engin B, serdalogru S. Basal Cell Carcinoma. Turkey: Istanbul University; 2011: 51-86. [cited 2014 Aug 01]
4. UCSF Medical Centre. Basal cell and squamous cell carcinoma. San Fransisco; 2014 [cited 2014 Feb 03].
5. Weedon D, Marks R, Kao GF, Harwood CA. Keratinocytic tumours: Introduction. In : LeBoit, PE, Burg G, Weedon D, Sarasin A. (editors).
Pathology and Genetics of Skin Tumours. World Health Organization Classification of Tumour. Lyon: IARC Press; 2003: p.11-19.
6. Flohil SC, Vries ED, Neumann M, Coeberg JW, Nijsten T. Incidence, Prevalence and Future Trend of Primary Basal Cell Carcinoma in the Netherland.Acta Derm Venereol.2011; 91: 24-30. [cited 2014 Feb 03]
7. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley GC, Weaver AL, et al. Incidence of Basal Cell and Squamous Cell Carcinomas in a Population Younger Than 40 Years.JAMA; 2005 Aug 9: 681-90. [cited 2014 Feb 03]
managementinAustralia.[Internet].2008Nov[cited2014Juli03];
http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/B
asal_cell_carcinoma_Squamous_cell_carcinoma_Guide_Nov_2008-Final_with_Corrigendums.pdf
9. Ricotti C, Bouzari N, Agadi A, Cockerell CJ. Malignant Skin Neoplasms. USA: Elsevier Inc; 2009 : 1241- 54. [cited 2013 Aug 01]
10. Chinem VP, Miot HA. Epidemiology of Basal Cell Carcinoma. Anais Brasileiros de Dermatologia. 2011; 86(2):292-305. [cited 2013 Aug 01]
11.Epstein EH. Basal cell carcinomas: Attack of the Hedgehog. USA; Mac Millan Publisher Limited; 2008: 743-754. [cited 2013 Aug 01]
12.Gu D dan Xie J. Research progress in the cell origin of basal cell carcinoma.World J Med Genet. Baishideng. 2011; 1(1):11-13. [cited 2013 Aug 01]
13.White GM, dan Cox NH. Malignant and Premalignant Epidermal Neoplasia. In:
Disease of the Skin. W.B. Saunders. USA.2002. [cited 2013 Aug 01]
14. Telfer NR, Colver GB dan Morton CA. Guidelines for the management of basal carcinoma. British Journal of Dermatology 2008; 159: 35-48. [cited 2013 Aug 01]
15. Wu PA. The Epidemiology of Basal Cell Carcinomas.UpToDate, Inc. [Internet]. 2014 [cited 2014Feb 03].
17. The Structure and Function of the Skin.[cited 2013 Aug 01]. www.advancedbodyworks.co.uk/docs/skinEssay.pdf.
18. Turner R. Basal Cell Carcinoma. Oxford: Oxford Redcliffe Hospital NHS Trust; 2011: 1-4. [cited 2014 Aug 01]
19. Oakley A dan Newman P. Cutaneus Tumours. DermNet NZ. New Zealand. 2012: 6. [cited 2014 Aug 01]
20. Hunter J, Savin J, Dahl M. Clinical Dermatology. 3th ed. Oxford: Blackwell Science Ltd; 2002: 265-67. [cited 2014 Aug 01]
21.Buljan M, Bulat V,Situm M,Mihic LL, Duktaj SS. Variation in Clinical Presentation of Basal Cell Carcinoma. Croatia: Acta Clin Croat; 2008: 25-30. [cited 2014 Aug 01]
22. The Skin Cancer Foundation. Basal Cell Carcinoma-Causes and Risk Factors.
New York. 2013 [cited 2013 Aug 01]. Tersedia di website:
http://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/bcc-causes-and-risk-factors
23. Haskell H. Histology of the Skin. In: Busam KJ (editor). Dermatopathology.
USA: Saunders, an imprint of Elsevier Inc; 2010: p.1-4. [cited 2014 Aug 01] 24. Basal cell carcinoma : possible role of some proliferative and apoptotic factors (
cited on 2014,Agustus 12). J Egypt wom Dermatol sac. Vol 6 No.1.2009. 25. Immunohistochemical nuclear staining for p53, PCNA, Ki67, and Bcl-2 in
26.Bcl-2 protein in aggresive and non aggresive basal cell carcinoma, ( cited on 2014, juli 13). Available: www.ncbi.nlm.nih.gov/pubmed/10885404.
27.BCL-2 (B-cell leukemia/lymphoma 2 .[cited2014,Juli20],available: http://atlasgeneticsoncology.org/Genes/BCL-21D49.html.
28.An overview of Bcl-2 expression in histopatological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis, and seborrheic keratosis.[cited2014,Juli20],available:www.ncbi.nlm.nih.
gov/pubmed/19138009
29.Hussain I, Sono M, Khan BS, Khan MD. Basal Cell Carcinoma Presentation: Histopathological Features and Correlation with Clinical Behaviour [Internet]; 2010 Jan: 3-7. [cited 2013 Aug 01]
30. Kumar, abbas, Fausto, Aster. Pathologic basis of Deases, 8Ed, Saunders, 2010. 31.Sanchez RL dan Raimer SS. Dermatopathology. Texas: Landes Bioscience,
Georgetown; 2001: p. 223-27.
32.Williams H, Bigby M, Diepgen T, Heirxheimer A, Naldi L, Rzany B. Evidence-based Dermatolog. London: BMJ Books; 2003: 324-43.
33.Wolff K, Allen RJ. Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology. 6th ed. New York: McGraw-Hill Medical; 2009: p. 287-95. 34.Ko CJ, Barr RJ. Dermatopathology: Diagnosis by First Impression.
UK:Wiley-Blackwell; 2011: 55-8. [cited 2013 Aug 01].
36. Hoff DDV, Lorusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. N Engl J Med 2009; 361: 1164-1172. [cited 2013 Aug 01]
37. Epidermal Growth Factor Receptor [cited 2014, Juli13] Available: Http://www.medicinenet.com.
38. Prognostic value of Ki-67, CD31 and epidermal growth factor reseptor ekspression in bacal cell carcinoma ( cited 2014, juli 13). Available: http://online library. Wiley.com
39. Aneuploidy, but not Ki-67 or EGFR ekspression is associated with rekurences in basal cell carcinoma. ( cited 2014, juli 13). Available: http://online library. Wiley.com.
40. Targeted Therapy in Nonmelanoma skin cancer, ( cited on 2014, Juli 13), canc. Available : www.mdpi.com/journal cancers
41. Wahyuni Sari Arlinda. Statistika kedokteran. Jakarta;2007.p.79-86.
42. Sastroasmoro Sudigdo, Ismael Sofian. Dasar-dasar metodologi penelitian klinis.edisi 3.sagung seto;2010.p.78-88.
